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The matrix (M) protein of vesicular stomatitis virus (VSV) plays significant roles in the replication of VSV through its involvement in the
assembly of virus particles as well as by facilitating the evasion of innate host cell defense mechanisms. The presence of methionine at position 51
(M51) of the matrix (M) protein of the VSV Indiana serotype (VSVInd) has been proven to be crucial for cell rounding and inhibition of host cell
gene expression. The M protein of VSVInd with the substitution of M51 with arginine (R:M51R) results in the loss of inhibitory effects on host cell
gene expression. The VSVInd expressing the M(M51R) protein became the attractive oncolytic virus which is safer and more tumor-specific
because the normal cells can clear the mutant VSVInd easily but tumor cells are susceptible to the virus because a variety of tumor cells lack innate
antiviral activities. We have studied the role of the methionines at positions 48 and 51 of the M protein of the New Jersey serotype of VSV
(VSVNJ) in the induction of cytopathic effects (CPE) and host cell gene expression. We have generated human embryonic kidney 293 cell lines
inducibly expressing M proteins with M to R mutations at positions 48 and 51, either separately or together as a double mutant, and examined
expression of heat shock protein 70 (HSP70) as an indicator of host cell gene expression. We have also generated recombinant VSVNJ encoding
the mutant M proteins M(M48R) or M(M48R+M51R) for the first time and tested for the expression of HSP70 in infected cells. Our results
demonstrated that the M51 of VSVNJ M proteins has a major role in cell rounding and in suppressing the host cell gene expression either when the
M protein was expressed alone in inducible cell lines or when expressed together with other VSV proteins by the recombinant VSVNJ. Amino acid
residue M48 may also have some role in cell rounding and in the inhibitory effects of VSVNJ M, which was demonstrated by the fact that the cell
line expressing the double substitution mutant M(M48R+M51R) exhibited the least cytopathic effects and the least inhibitory effect on host cell
gene expression.
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Vesicular stomatitis virus (VSV), the prototype virus of the
Rhabdoviridae, induces typical cell rounding that leads to the
lysis of infected eukaryotic cells (Simon et al., 1990). Although
the 48 nucleotide-long, plus-sense leader RNA or other
components of VSV have been implicated as the cause of the
CPE byVSV (Grinnell andWagner, 1983; Kopecky et al., 2001),
the well documented cause of CPE has been the expression of the
matrix (M) protein during VSV replication. The direct and⁎ Corresponding author. Fax: +1 519 661 3359.
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doi:10.1016/j.virol.2006.07.022indirect mechanisms by which the M protein induces CPE are
disorganization of cytoskeletal elements such as actin or tubulin
by associationwith them (Blondel et al., 1990;Melki et al., 1994)
and general inhibition of host cell gene expression (Black and
Lyles, 1992), which can result in the systemic breakdown of the
cell by apoptosis (Kopecky and Lyles, 2003).
VSV has two major serotypes: Indiana (VSVInd) and New
Jersey (VSVNJ). Matrix proteins of both VSVInd and VSVNJ
have 229 amino acids with about 59%–62% amino acid
sequence identity (Gill and Banerjee, 1986). In addition to the
first methionine, 2 other methionines are conserved at positions
33 (M31) and 51 (M51) in both M proteins of VSVInd and
VSVNJ within the NH2-terminal 51 amino acids. It has been
42 G.N. Kim, C.Y. Kang / Virology 357 (2007) 41–53suggested that these two methionines may play a role in
producing truncated M proteins via internal translation initiation
and in the induction of cell rounding by VSVInd (Jayakar and
Whitt, 2002). The VSVNJ is further divided into two subtypes,
Hazelhurst strain [VSVNJ(Haz)] and Ogden strain [VSVNJ
(Ogd)]. One additional methionine is present at position 48 in
the VSVNJ(Haz) M protein and 2 additional methionines are
present at positions 21 and 48 in the VSVNJ(Ogd) M protein.
The M48 is conserved in the M proteins of both VSVNJ(Haz)
and VSVNJ(Ogd) and is closely placed to the M51, indicating
that M48 may have a role in the cytopathogenesis induced by
the M protein.
It has been demonstrated that the VSV M protein inhibits the
expression of host cell proteins by inhibiting cellular transcrip-
tion (Ahmed and Lyles, 1998; Black and Lyles, 1992) and by
blocking the nuclear export of a broad range of cellular RNAs
including spliced mRNAs (Her et al., 1997). The amino acid
residue in the M protein of VSVInd, which is critical for the
inhibition of host cell gene expression, is the methionine at
position 51 (M51). The importance of the M51 for the inhibition
of host cell gene expression was first indicated by the
conditional temperature-sensitive M mutant of VSVInd, tsO82
(Coulon et al., 1990). It has been demonstrated that M51 of
VSVInd M protein has a major role in disrupting nucleocyto-
plasmic transport of mRNAs by binding directly to components
of the nuclear pore complex such as Nup98, one of the
nucleoporins (Enninga et al., 2002; Petersen et al., 2001, 2000;
von Kobbe et al., 2000), and/or by interrupting the interaction
between Nup98 and Rae1/mrnp41 (Faria et al., 2005), a
shuttling mRNA export factor that is bound by M protein as
well. Replacement of M51 with either arginine (R), alanine (A),
leucine (L) or aspartic acid (D) reduced the inhibitory effect of
M protein on the nuclear export of cellular RNAs (Petersen et
al., 2000; von Kobbe et al., 2000).
VSV became an attractive oncolytic agent for cancer therapy
because of its wide host cell range, rapid replication and mild
pathogenicity in humans. Because VSV M proteins having the
M51R mutation lack the inhibitory effect on host cell gene
expression, VSV expressing the mutant M protein loses the
means to counteract the antiviral activity of host cells such as
interferon (IFN) induction (Ahmed et al., 2003) and overall
inhibition of translation mediated by PKR activation. The
cancer cells are impaired with responsiveness to both type I
(IFN-α, -β) and type II IFN (IFN-γ), which is one of the
important innate host defense mechanisms against viral
infection (Balachandran and Barber, 2004). In addition,
transformed cells have an increased level of eIF2Bε, a catalytic
subunit of eIF2B and a guanine nucleotide exchange factor
(Balachandran and Barber, 2004). The subunits of eIF2B are
involved in converting the inactive form of eIF2·GDP to the
active eIF2·GTP, which is required to form a eukaryotic
translation initiation complex. The activity of eIF2B is normally
reduced in the non-tumor cells by the activation of IFN-induced
RNA-dependent protein kinase PKR and eIF2α phosphoryla-
tion. The lack of innate defense mechanisms in transformed
cells makes them more susceptible to the VSV infection than
primary cells (Balachandran and Barber, 2004; Stojdl et al.,2000; Stojdl et al., 2003). VSV expressing the M protein with
M51R mutation [M(M51R)] can be readily cleared from normal
cells by an antiviral defense mechanism, whereas the trans-
formed cells which lack the antiviral activity are equally well
infected and lysed by both the mutant and wild type VSV. These
characteristics of the transformed cells and VSV expressing M
(M51R) have resulted in the mutant VSV being considered as a
safer and tumor-cell-specific oncolytic agent.
In this study, we examined the effects of the M33, M48 and
M51 of the VSVNJ M protein on host cell gene expression and
cell death. We generated tetracycline-inducible cell lines
expressing VSVNJ M mutants which contained individual
substitutions of arginines at positions M33, M48 and M51 and a
double substitution of both positions M48 and M51. Recombi-
nant VSVNJ was recovered from cDNA for the first time, and
the activity of mutant M proteins with the M48R or M48R+
M51R mutations encoded within the recombinant virus was
also examined. Our results demonstrated that M51 of VSVNJ M
protein has a major role in the induction of cell rounding and
inhibition of host cell gene expression either when the M
protein was expressed alone or when expressed together with
other VSV proteins. Amino acid residue M48 may be partially
responsible for the cell rounding and the inhibitory effect on
gene expression, as demonstrated by the least cytopathic effects
and the least inhibitory effects on the host cell gene expression
in the cell line expressing the double mutant M(M48R+M51R)
of VSVNJ.
Results
Transient expression of wild type and mutant matrix proteins of
VSVNJ
Matrix proteins of both VSVInd and VSVNJ consist of 229
amino acids with about 60% amino acid sequence identity. The
NH2-terminal regions of M proteins from both serotypes are
highly basic, and the hydrophobic region and the PPPY motif
that are involved in virus budding (Jayakar et al., 2000) are also
conserved. Both serotypes of VSV possess methionines at
positions 33 and 51 within the NH2-terminal 51 amino acids of
the M protein. The M33 and M51 of the VSVInd M protein have
been shown to play important roles in cell rounding (Jayakar
and Whitt, 2002) and in inhibiting host cell gene expression
(Ahmed et al., 2003; von Kobbe et al., 2000). There is one
additional methionine at position 48 in the VSVNJ M protein
(Fig. 1). In order to examine the importance of the methionines
at positions 33, 48 and 51 in the CPE and inhibitory effects on
the host cell gene expression by the VSVNJ M proteins,
individual or combined methionine to arginine mutations were
introduced (Fig. 1).
It has been demonstrated previously that the expression of
VSVInd M proteins from eukaryotic expression vector is self-
limiting (Black and Lyles, 1992; Blondel et al., 1990) as it acts to
inhibit its own transcription. Therefore, we cloned the wild type
andmutantM gene cDNAs into two separate plasmid expression
vectors in which the transcription is driven by the bacteriophage
T7 transcriptional promoter (pBKS-M) or by the eukaryotic
Fig. 1. Amino acid sequence comparison between M proteins of VSVInd and VSVNJ within 51 amino acids from the NH2-terminus and M to R mutations. Methionine
residues are bold faced. Individual mutations at positions 33, 48 and 51 are shown as M33R, M48R and M51R and double mutation at positions 48 and 51 is shown as
M48R+M51R.
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ofM protein was examined by transfecting recombinant vaccinia
virus vTF7-3 infected BHK21 cells with cDNA plasmids of the
wild type and mutant M genes. CMV promoter mediated
expression of M protein was examined by transfecting BHK21
cells with pcDNA5-M clones without vTF7-3 infection. The
transfected cells were labeled with 35S-met for 3 h at 20 h post
transfection, and the M protein was immunoprecipitated using
polyclonal antiserum against VSVNJ whole virus. High levels of
all mutant and wild type M proteins [M(wt)] were expressed by
the T7 RNA polymerase that was provided by the recombinant
vaccinia virus in the cytoplasm (Fig. 2A). Compared to the T7
promoter driven expression of M proteins, CMV promoterFig. 2. Transient expression of VSVNJ wt and mutant M proteins. (A) Expression o
confluence in 6 well culture plates were infected at an MOI of 6 with recombina
polymerase. The infected cells were transfected with 7.5 μg of pBKS-MNJ(M33R), pB
with 30 μCi/ml 35S-met for 3 h at 20 h post transfection. The labeled cells were lysed w
deoxycholate, 10 mMNa2EDTA), and M proteins were immunoprecipitated using po
CMV promoter. BHK21 cells at 70% confluence in 100 mm culture dishes were tran
(M48R), pcDNA5-MNJ(M51R) or pcDNA5-MNJ(M48R+M51R) and labeled with 30
and M proteins were immunoprecipitated using polyclonal antiserum against VSVNdriven expression of M protein was only detectable in cells
transfected with pcDNA5-M(M51R) and pcDNA5-M(M48R+
M51R) (Fig. 2B). The results suggest that methionine at 51 of
VSVNJM protein has a critical role in inhibiting gene expression
by the host cellular RNA polymerase as has been demonstrated
by the M51 substitution of VSVInd M protein.
Replacement of methionine with arginine at positions 33, 48
and 51 in the VSVNJ M protein does not affect the budding
activity of VSVNJ M protein
It has been demonstrated that M to R mutations at positions
33 and/or 51 in the VSVInd M protein do not affect the assemblyf M proteins mediated by the bacteriophage T7 promoter. BHK21 cells at 90%
nt vaccinia virus vTF7-3 expressing bacteriophage T7 DNA-dependent RNA
KS-MNJ(M48R), pBKS-MNJ(M51R) or pBKS-MNJ(M48R+M51R) and labeled
ith 400 μl of lysis buffer (10 mMTris–HCl, pH 7.4, 1%Nonidet P-40, 0.4% Na-
lyclonal antiserum against VSVNJ. (B) Expression of M proteins mediated by the
sfected with 30 μg of pcDNA5-MNJ(wt), pcDNA5-MNJ(M33R), pcDNA5-MNJ
μCi/ml of 35S-met for 3 h at 20 h post transfection. The labeled cells were lysed,
J.
Fig. 3. Substitutions of methionines to arginines at positions 33, 48 and 51 in the
VSVNJ M protein do not affect its role in virus budding. VSVNJ panhandle type
DI particle NJDI(227-188) was recovered by cotransfecting pTV-HDI(227-188),
pBKS-NNJ, pBKS-PNJ, pBKS-GNJ, pBKS-LNJ and pBKS-MNJ (wt or M to R
mutants) as described previously (Kim and Kang, 2005). The presence of the DI
particle genomic RNA was detected by Northern blot analysis using the DI
particle genome specific riboprobe.
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2002). In order to study the effects of M to R changes at
positions 33, 48 and 51 in the VSVNJ M protein on the assembly
and budding of VSVNJ, we recovered VSVNJ panhandle DI
particles from the cDNA using the VSV reverse genetics system
(Kim and Kang, 2005). Since the panhandle type VSV DI
particle contains all the necessary cis-acting sequences at the 3′
and 5′ termini of its genome for replication and budding, the
recovery of the DI particles using the wild type and mutant
VSVNJ M proteins was ideal for this study. VSVNJ DI particles
containing bacteriophage λ sequences NJDI(227-188) (Kim and
Kang, 2005) were recovered from cDNA using either the wild
type or mutant VSVNJ M proteins as described in the Materials
and methods. The recovered DI particles were amplified once
by coinfecting BHK21 cells with an MOI of 3 of the standard
VSVNJ in a 6 well culture plate. At 15 h postinfection, 2 ml of
culture fluid containing amplified DI particles and VSVNJ
standard virus was collected. Fresh BHK21 cells in a 6 well
culture plate were infected with 300 μl of the harvested culture
media. At 5 h postinfection, the cells were lysed and DI particle
RNA was isolated as described previously (Kim and Kang,
2005). The presence of bacteriophage λ sequences in the
extracted DI particle RNA was determined by Northern blot
analysis using a λ-specific riboprobe. Correct sizes of NJDI
(227-188) genomic RNA were detected in all of the cells
infected with recovered DI particles (Fig. 3). This result
demonstrates that the respective M to R mutations at positions33, 48 and 51 do not affect the assembly and budding function
of the VSVNJ M protein.
VSVNJ M protein with M48R+M51R double mutation is the
least cytopathic
Examination of the effects of the M protein on cell rounding
and host cellular gene expression by transfection of DNA
plasmid is not suitable because all cells are not transfected
equally and the M protein can inhibit its own expression from
the plasmid, resulting in overall insufficient effects on cells. In
order to circumvent the self-limiting expression of M proteins
from the plasmid DNA, other researchers have used mRNAs of
the M protein gene that were prepared by in vitro transcription
to transfect the cells (Ahmed and Lyles, 1998; Lyles and
McKenzie, 1997). But the results from the transfection of
mRNA can be variable depending on the transfection efficiency.
In order to have all the cells in the culture dish express M
protein and because a very small quantity of M protein can
induce cytopathic effects (Black and Lyles, 1992), we generated
tetracycline-inducible human 293 cell lines which express wild
type M protein: M(wt), two single mutants: M(M48R) and M
(M51R), and one double mutant: M(M48R+M51R). The
results shown in Fig. 2B suggest that M(wt) and M(M33R)
have the same effect on host cell gene expression. Therefore, we
were interested to know the outcome of M48 and M51
mutations to arginine. In order to examine the role of
methionines at positions 48 and 51, separately and together,
each inducible cell line was treated with 1 μg/ml of tetracycline
for 24 h to induce M protein expression. The cell lysates were
prepared to detect the expression of M proteins by Western blot
analysis using polyclonal antiserum against whole VSVNJ.
Most of the cells expressing M(wt) were rounded up and
detached (Fig. 4A-1), whereas cells expressing M(M48R)
showed less cytopathic effect than the cells expressing M(wt)
(Fig. 4A-3). Most of the cells expressing M(M51R) or M
(M48R+M51R) remained attached to the culture dish with only
slight cell rounding (Fig. 4A-5 and -7). Although the cell lines
expressing M(wt) and M(M48R) proteins showed pronounced
CPE indicating the presence of M proteins in the cells, we could
only detect the expression of M proteins in the cell lines
expressing M(M51R) and M(M48R+M51R) by Western blot
analysis (Fig. 4B, lanes 4 and 5). This result is consistent with
the previous observation that a minute quantity of M protein can
be detrimental to host cells (Black and Lyles, 1992). Our result
demonstrates that M51 in the VSVNJ M protein plays a major
role in the inhibition of cell rounding in 293 cells whereas M48
may have little effect on the cell rounding.
It has previously been demonstrated that the M(wt) protein of
VSVInd alone causes apoptosis in BHK cells and HeLa cells
(Kopecky et al., 2001). The induction of apoptosis was closely
related to the presence of M51 in the M protein and inhibition of
host cellular gene expression by the M protein, which was
demonstrated using the M51R mutant. Therefore, we examined
the effects on apoptosis of M to R mutations in the VSVNJ M
protein at positions 48 and 51, both individually and together.
Approximately 5×106 cells in a 60 mm culture dish were
Fig. 4. Mutations at positions M48 andM51 of VSVNJ M protein have the greatest impact on the reduction of cytopathic effects. Tetracycline-inducible human 293 cell
lines expressingM(wt) or M proteins with M to R mutations at positions 48 and 51 individually and together were generated. The cell lines were treated with 1 μg/ml of
tetracycline for 24 h to induce the expression of M proteins (A) Pictures were taken at 24 h after the treatment of cells with tetracycline at 125× magnification. (B) The
expression of M proteins was examined by Western blot analysis using the cell lysate and polyclonal antiserum against VSVNJ.
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expression and cell lysates were used to isolate low molecular
weight DNAs for the DNA fragmentation assay (Fig. 5A) and toFig. 5. VSVNJ M protein with double mutations at both M48 and M51 show the grea
from the cell lines treated or untreated with tetracycline. The isolated DNAwas resolv
(wt) or mutant M proteins were examined as described in the Materials and methods. C
wave length 405 nm. The error bar represents the standard deviation of the mean fro
(M48R+M51R): P=0.0421.determine the caspase-3 activity by colorimetric assay (Fig. 5B).
Both apoptotic assays demonstrated that M(wt) induces the
strongest apoptotic effect (Fig. 5A, lane 1 and Fig. 5BWTw/tet),test reduction in apoptotic activity. (A) Low molecular weight DNAwas isolated
ed on a 1.5% agarose gel. (B) The caspase-3 activities in cell lines expressing M
aspase-3 activity is depicted as optical density (O.D.) unit which was read at the
m triplicate assays. The paired two tailed t test on samples of M(M51R) and M
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to about 2/3 level of the wild type M (Fig. 5A, lane 3 and Fig.
5B). The substitution of M51 with R either in the single mutant
M(M51R) or double mutant M(M48R+M51R) reduced the
apoptotic activity of VSVNJM close to background levels, and it
showed that the substitutions at both positions 48 and 51 led to a
complete shutdown of caspase-3 induction (Fig. 5A, lane 5 and 7
and Fig. 5B). Therefore, we conclude that the methionines at
positions 48 and 51 are required for efficient apoptosis of human
293 cells expressing the VSVNJ M protein.
VSVNJ M protein with M48R+M51R mutation loses its
inhibitory effect on host cellular gene expression
Human 293 cells express heat shock protein 70 (HSP70)
constitutively with or without heat treatment (Theodorakis and
Morimoto, 1987) as shown in Fig. 6, lanes 10 and 11. Therefore,
we chose the expression of HSP70 as an indicator to test the
inhibitory effect of wild type and mutant M proteins of VSVNJ
on host cell gene expression.
In order to examine the effects of the mutations of the M
protein on the expression of HSP70, the expression of M
protein was induced first by treating the cell lines with 1 μg/
ml of tetracycline followed by heat shock at 44 °C for 10 min
to induce the HSP70. The expression of HSP70 was
determined by labeling the cell with 30 μCi/ml of 35S-met
for 2 h at 3 h after heat shock and immunoprecipitating the
HSP70 using a monoclonal antibody against human HSP70.
The expression of M proteins in the same cell lines was
examined by labeling the cells with 35S-met at 20 h after theFig. 6. A methionine at position 51 of the VSVNJ M protein is critical for
blocking host cell gene expression. (A) Human 293 cell lines expressing VSVNJ
M(wt), M(M48R), M(M51R) and M(M48R+M51R) were treated with 1 μg/ml
of tetracycline. After 4 h treatment with tetracycline, the cells were heat shocked
for 10 min at 44 °C. The expression of HSP70 was determined by labeling the
cells with 30 μCi/ml of 35S-met for 2 h at 3 h after the heat shock and
immunoprecipitating the HSP70 using a monoclonal antibody against human
HSP70. The expression of M protein in the same cell lines was determined after
the heat shock by labeling the cells with 35S-met at 20 h after the induction of M
protein. The M protein was immunoprecipitated using the antibody against
VSVNJ. HSP70 denotes heat shock protein 70. VSVNJ denotes the M protein
expressed in the cells infected with wild type VSVNJ. M on the lower panel
denotes the wild type and mutant VSVNJ M proteins. Tet denotes tetracycline.induction of the M protein. The M protein was immunopre-
cipitated using the antibody against VSVNJ. There was a slight
increase in the expression of HSP70 in the parental human
293 cells after heat shock (Fig. 6, lanes 10 and 11). In the
absence of M protein expression, all cell lines expressed levels
of HSP70 similar to those of the control parental 293 cells
(Fig. 6, lanes 2, 4, 6, 8, 10 and 11). The cell lines expressing
M(M51R) and M(M48R+M51R) showed similar levels of
HSP70 expression to those which were not treated with
tetracycline (Fig. 6, lanes 7 and 9). However, the expression
of HSP70 was decreased significantly in cell lines expressing
M(wt) and M(M48R) (Fig. 6, lanes 3 and 5).
Next we examined whether or not the M51R mutation
continues to reduce cytopathogenicity and inhibition of host cell
gene expression in the presence of other VSVNJ proteins. In
order to address this question, we generated full-length cDNA
clones of VSVNJ and recovered the viruses containing M genes
which encode M(wt), M(M48R) and M(M48R+M51R)
separately. The cloning of the full-length genome (Fig. 7) and
recovery of VSVNJ from the cDNA clone were carried out by
reverse genetics as described in Materials and methods. The
growth rates of recombinant VSVNJ, rWT, rM(M48R) and rM
(M48R+M51R) were determined by infecting BHK21 cells and
human 293 cells at an MOI of 3. Both wild type and mutant
viruses showed similar patterns of replication in both cell lines,
although the viruses replicated slower in the human 293 cells
compared to the BHK21 cells (Fig. 8). The VSVNJ expressing M
(M48R) or M(M48R+M51R) replicated slower than the viruses
expressing M(wt) during the first 6 h after infection (Fig. 8). The
recombinant viruses reached a peak titer at 8 h postinfection
when the viruses were grown in human 293 cells and
maintained similar level of replication until 10 h postinfection
(Fig. 8B). In order to examine the effect of VSVNJ expressing M
(M48R) or M(M48R+M51R) on the host cellular protein
synthesis, human 293 cells were infected with the recombinant
VSVNJ at an MOI of 6 and the infected cells were labeled with
30 μCi/ml of 35S-met for 1 h at 8 h postinfection. Overall
cellular protein synthesis and VSVNJ protein synthesis were
examined by SDS-PAGE using equal amounts of cell lysates
(15 μg), which was demonstrated by staining the gel with
Coomassie blue (Fig. 9A) and by Western blot analysis of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the
same samples (Fig. 9B, lower panel). The 35S-met labeled
proteins were visualized by autoradiography (Fig. 9B, upper
panel). The remaining cell lysates were divided into two
aliquots for immunoprecipitation using the antibody against
HSP70 and the antibody against VSVNJ. The substitution of M
with R at positions 48 and 51 in the M protein made migration
of the M protein slightly faster than that of the wild type (Fig. 2),
and the pattern was also shown in the cells infected with the
recombinant VSVNJ expressing M(M48R) and (M48R+M51R)
(Figs. 9B and C, upper panel, lanes 3 and 4), demonstrating that
the recombinant viruses expressed mutant M proteins. The
overall protein synthesis was maintained at about 60% and 25%
of uninfected cells in the cells infected with rM(M48R+M51R)
or rM(M48R) compared to the 2% to 12% protein synthesis in
cells infected with wild type virus (Fig. 9B). The results
Fig. 7. Schematic representation of the generation of full-length cDNA clones of VSVNJ. The restriction enzyme sites in the vector (SapI and RsrII) and in the VSV
genome (AvaI, PflMI and NdeI) for the assembly of the full length are shown on the top of the panel. The restriction enzyme sites that cut once (NotI and KpnI) and
twice (PacI) were introduced into the untranslated regions at the P gene, M gene and G gene. The cDNAs of the mutant viruses rM(M48R) and rM(M48R+M51R)
were generated by using the PacI and NotI sites to replace the wild type M gene.
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on the host cellular protein synthesis significantly and
substitution of M48R has slight effects on the host cell gene
expression in cells infected with VSVNJ. The overall VSV
protein synthesis was also increased in cells infected with rM
(M48R+M51R) compared to the cells infected with wild typeFig. 8. Single cycle growth curve of wild type and methionine to arginine substitut
infected at an MOI of 3 of the viruses. After 1 h of adsorption, the infected cells were w
dish as a sample at 0 h. The same volumes (500 μl) of culture media were taken a
determined by standard plaque assay. The viral titer at each time point represents thor with rM(M48R) (Fig. 9B, lane 4), which demonstrates that
decreased inhibition of host cellular protein synthesis correlates
with increased VSV protein synthesis. The expression of
HSP70, an indicator for host cell gene expression, decreased to
an undetectable or significantly low level in cells infected with
wild type VSVNJ and VSVNJ M(M48R) respectively (Fig. 9C,ion mutant viruses of VSVNJ. BHK21 cells (A) and human 293 cells (B) were
ashed twice and 500 μl of culture media was taken immediately from the culture
nd fresh media were added every 2 h until 10 h postinfection. Viral titer was
e average of triplicate experiments.
Fig. 9. Recombinant VSVNJ expressingM(M48R+M51R) does not block cellular gene expression. (A) Human 293 cells were infectedwith wild type, recombinant wild
type, rM(M48R) or rM(M48R+M51R) viruses at an MOI of 6, labeled with 30 μCi/ml of 35S-met for 1 h at 8 h postinfection. The cell lysates were analyzed by SDS-
PAGE, and the gel was stainedwithCoomassie blue to demonstrate that equal quantities (15μg) of sampleswere loaded. (B) The gel was dried and exposed toX-ray film.
The amount of GAPDH in 15 μg of each cell lysate was determined byWestern blot analysis using a polyclonal antibody against human GAPDH. The bar graph on the
right side of the panel shows the percent expression of total protein synthesis compared to that of uninfected cells, which was determined bymeasuring the optical density
of protein bands between large proteinL andglycoproteinGofVSVon the autoradiographed film.The error bars on the graph represent the standarddeviations of themean
from triplicate samples. (C) HSP70 andVSVNJ proteins were immunoprecipitated separately from the cell lysate using amonoclonal antibody against humanHSP70 and
polyclonal antibody against VSVNJ (Kim et al., 2002). The upper panel shows the VSVNJ proteins immunoprecipitated by mixed polyclonal antibodies against VSVNJ
whole virus and antibody against VSVNJ L protein. The lower panel shows the expression of HSP70 in the same cells from which the VSVNJ proteins were detected.
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(M48R+51R) expressed levels of HSP70 equivalent to about
60% of uninfected cells (Fig. 9C, lanes 4 and 5). The results
demonstrate that the M51 in the VSVNJ M protein, as with the
VSVInd M protein, plays a major role in the blocking of host cell
gene expression. The results also suggest that M48 may have a
slight effect in blocking host cell gene expression.
Discussion
VSV, a single stranded negative sense RNA virus, has
become a useful tool for the treatment of cancer (Balachandran
et al., 2001; Ebert et al., 2005; Obuchi et al., 2003; Stojdl et al.,
2003) and for the expression of antigens in host animals to
induce immune responses (Egan et al., 2004; McKenna et al.,
2003; Rose et al., 2001). As an oncolytic viral agent, VSV
which encodes the mutant M protein that has lost its inhibitory
effect on host cell gene expression is gaining attention as an
alternative virus to wild type VSV because of its improved
safety (Ahmed et al., 2004; Ebert et al., 2004; Stojdl et al.,
2003). All of the works on VSV as an oncolytic virus and as a
foreign gene delivery vector have been performed using
VSVInd. Another serotype of VSV, VSVNJ, which is not
neutralized by antibodies against VSVInd has not yet been
generated as a recombinant virus from cDNA. Here we have
investigated the effects of M to R mutations at positions 33, 48
and 51 of VSVNJ M protein on CPE and host cell gene
expression using cell lines which express M protein, as well as
recombinant VSVNJ which expresses the wild type M protein or
the mutant M proteins. Double substitutions at M48 and M51
with R in the VSVNJ M protein, both in cells expressing the
protein alone or from the recombinant VSVNJ, showed a drastic
reduction of inhibitory effects on host cell gene expression.
The NH2-terminal region of the VSV M protein contains
important amino acid residues required to support the replica-
tion of VSV during virus particle assembly and escape from
innate cellular antiviral activity. The PPPY motif from positions
24 to 27 is critical for VSV budding from the cell surface
(Craven et al., 1999; Jayakar et al., 2000). The translation
codons for M33 and M51 in the VSVInd M protein have been
suggested as being used for the synthesis of two additional
NH2-terminally truncated M proteins, which have been
suggested to be responsible for cell rounding (Jayakar and
Whitt, 2002). It has been demonstrated that the M51 of the
VSVInd M protein is involved in its association with
nucleoporins, which leads to the blocking of nucleocytoplasmic
transport of cellular RNAs and in inhibiting overall cellular
gene expression (Coulon et al., 1990; Petersen et al., 2000; von
Kobbe et al., 2000). The VSVNJ M protein has three
methionines at the NH2-terminal region, M33, M48 and M51.
M33 and M51 are conserved in both VSVInd M and VSVNJ M
proteins. When the VSV M protein is expressed from a plasmid
containing a eukaryotic promoter, a very small quantity of M
protein can inhibit its own synthesis from the plasmid (Black
and Lyles, 1992; Blondel et al., 1990), which can reflect the
effect of inhibition of host cellular gene expression by the M
protein. When we expressed the mutant VSVNJ M proteins fromthe eukaryotic plasmid vector, or in tetracycline-inducible cell
lines, VSVNJ M proteins containing the M51R mutation, M
(M51R) and M(M48R+M51R), were detected in good quantity,
however, little to no M protein was detected in M(M48R) or M
(wt) expressing cell cells (Figs. 2B and 4B). This indicates that
it is mostly the M51 of VSVNJ M protein which is involved in
the inhibition of host cell gene expression as in VSVInd. M48 is
conserved in M proteins of both VSVNJ(Haz) and VSVNJ(Ogd)
strains. Although the single mutation at M48R does not affect
the inhibitory effect of the VSVNJ M protein significantly, the
substitution of both M48 and M51 together as in the M(M48R+
M51R) caused an increased reduction of its inhibitory effects on
host cell gene expression relative to that of the single mutation
M51R (Figs. 4B and 6). This result demonstrates that both M48
and M51 may be involved in binding nuclear pore complexes
such as Nup 98 (von Kobbe et al., 2000). The apoptotic cell
death induced by the VSVInd M protein is closely related to the
inhibition of host cell gene expression by the M protein
(Kopecky and Lyles, 2003; Kopecky et al., 2001). Therefore,
the more the M protein loses its inhibitory effects on the host
cell gene expression, the less it is capable of inducing CPE and
apoptosis, which was demonstrated by the M(M48R+M51R)
of VSVNJ in our experiments (Figs. 4A and 5). Although the M
protein with M48R mutation inhibits the production of HSP70
expression when it is expressed alone in the tetracycline-
inducible cell line (Fig. 6), the cellular caspase-3 activity and
subsequent DNA fragmentation was reduced significantly with
the M48R mutation compared to the wild type M protein (Fig.
5). In addition, the M48R and M51R double mutation resulted
in a much higher level of M protein synthesis compared to the
M51R single mutation in cell lines expressing the M proteins
(Fig. 4B). These results indicate that not only the M51R
mutation but also the M48R mutation is required for optimal
reduction of cytotoxicity in infected cells. Thus, it is desirable to
change methionines at both positions M48 and M51 to arginines
to generate VSVNJ as a gene expression vector or an oncolytic
virus.
Although VSV is a rapidly replicating virus which can infect
tumor cells quickly, eventually humoral and cellular immune
responses against VSV will be elicited in the animal host
(Kalinke et al., 1996; Puddington et al., 1986; Yewdell et al.,
1986). An animal infected with VSV develops immune
responses within 1 or 2 weeks (Kalinke et al., 1996) and starts
to neutralize the VSV, which makes the cancer treatment or
foreign gene delivery via VSV incomplete. This hinders the
efficacy of additional treatments for cancer therapy or boost
immunizations for vaccination with the same vector. The two
different serotypes of VSV, VSVInd and VSVNJ, show 50%
amino acid identity in the glycoprotein (Gallione and Rose,
1983). Antibodies raised against one serotype of VSV do not
neutralize the other serotype of VSV (Cartwright and Brown,
1972). Therefore, others have used VSVInd as a vaccine vector
in which the glycoprotein was replaced with that of VSVNJ to
minimize the problems arising from this immune response
against the viral vectors (Rose et al., 2001, 2000). Although the
VSVInd with G protein replaced with VSVNJ serotype is useful
in evading the humoral immune response, it will not prevent the
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capsid or matrix proteins. The cellular immune responses
against VSV proteins other than the G protein may result in
incomplete immune responses against the antigen of interest or
failure to complete oncolytic treatment. Therefore, the genera-
tion of additional recombinant VSV from another serotype can
increase the efficacy of using VSVas an oncolytic virus and as a
live viral vaccine vector. Our data show that VSVNJ encoding M
(M48R+M51R) loses its inhibitory effect on host cell gene
expression (Fig. 9), thereby making it a good candidate for more
efficient cancer therapies. In addition, recombinant VSVNJ is an
effective viral vector for the expression of foreign genes, which
can be used to minimize problems associated with preexisting
immune responses against VSV itself.
Materials and methods
Cells and viruses
BHK21 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 5% fetal bovine serum
(FBS). Flp-In T-REx 293 cells (Invitrogen) were cultured in
DMEM containing 10% FBS, 100 μg/ml zeocin and 15 μg/ml
blasticidine. Tetracycline-inducible Flp-In T-REx 293 cells
expressing VSVNJ wild type or VSVNJ M protein mutant were
cultured in DMEM containing 10% FBS, 15 μg/ml blasticidine
and 400 μg/ml hygromycin B. The BHK cell line expressing T7
RNA polymerase, BSRT7/5 (Buchholz et al., 1999), was grown
in DMEM containing 5% FBS and 500 μg/ml geneticin.
Recombinant VSVNJ was generated from the VSVNJ(Haz)
strain (Dr. S. Emerson, NIH, Bethesda, MD). The recombinant
and wild type VSVNJ were purified 3 times by plaque picking
and amplified in BHK21 cells. Recombinant vaccinia virus
expressing T7 DNA-dependent RNA polymerase, vTF7-3
(Fuerst et al., 1986), was prepared in TK− 143 cells as
described previously (Mackett et al., 1985).
Plasmids
Construction of cDNA clones of VSVNJ(Haz) genes in the
pBluescript II KS vector (pBKS; Stratagen), pBKS-NNJ, pBKS-
PNJ, pBKS-MNJ, pBKS-GNJ and pBKS-LNJ has been described
previously (Kim et al., 2002; Kim and Kang, 2005). Plasmids
encoding VSVNJ M protein mutants under the control of the T7
promoter, pBKS-MNJ(M33R), pBKS-MNJ(M48R), pBKS-MNJ
(M51R) and pBKS-MNJ(M48R+M51R), were generated in
pBKS-MNJ by megaprimer PCR-based site-directed mutagen-
esis (Sarkar and Sommer, 1990). The schematics and primers
for the construction of mutant pBKS-MNJ are described in
supplement 1. Plasmids expressing VSVNJ wild type and
mutant M under the control of the CMV promoter were
constructed by inserting DNA fragments of M genes from the
pBKS-MNJ wild type and the mutants into the NotI site of
pcDNA5/FRT/TO (Invitrogen). The resulting plasmids were
designated as pcDNA5-MNJ(wt), pcDNA5-MNJ(M33R),
pcDNA5-MNJ(M48R), pcDNA5-MNJ(M51R) and pcDNA5-
MNJ(M48R+M51R).VSVNJ nucleocapsid (N), phosphoprotein (P) and Large
protein (L) gene clones in the pBKS vector containing internal
ribosome entry site (IRES) of the encephalomyocarditis virus
(EMCV) 5′-untranslated region (pBKS-IRES/NNJ, pBKS-
IRES/PNJ and pBKS-IRES/LNJ) were generated by inserting
IRES sequences to the upstream of each gene. First, the IRES
sequence was amplified from the pTM1 vector (Elroy-Stein et
al., 1989) by polymerase chain reaction (PCR) using the primers
IRES5′ and IRES3′ and then cloned into the pBKS vector using
a NotI site, resulting in the pBKS-IRES. After confirmation of
the correct IRES sequence in the pBKS-IRES, the IRES
sequence was cut with NotI and inserted upstream of the VSVNJ
gene cDNAs in the pBKS-NNJ, pBKS-PNJ and pBKS-LNJ, with
the interrupting sequences remaining between the IRES and the
beginning of each gene. In order to use the 11th AUG sequence
in the IRES as a start codon without interruption of any other
sequence between the IRES and each gene sequence, the DNA
fragments containing continuous sequences from the end of the
IRES to the beginning of the respective gene were amplified by
megaprimer PCR (Sarkar and Sommer, 1990). The regions
containing extra sequences were replaced by the megaprimer
PCR products. Briefly, the megaprimers containing the 3′ 132
nucleotides (nts) of the IRES and beginning the NNJ, PNJ and
LNJ gene sequences were amplified by the first PCR using a
primer IRES-375 and pairing primers IRES-HN, IRES-HP and
IRES-HL for respective genes. The first PCR products were
purified and used with primers HN BglII, HPMfeI and HL PflfI
for the second PCR to amplify the continuous sequences
encompassing the 3′ IRES 132 nts and various lengths of N, P
and L gene 5′ sequences.
The full-length cDNA clone of the VSVNJ genome was
constructed by assembling four RT-PCR products and three
PCR products into the transcription vector pTV (Kim et al.,
2002; Pattnaik et al., 1992). The 7 PCR products were put
together sequentially, and finally the NdeI digest from pBKS-
LNJ was cloned into the previously assembled cDNA clone (Fig.
7). The full-length cDNA clone of VSVNJ was named as pTV-
VSVNJ(rwt). The full-length antigenomic RNA of VSVNJ is
encoded from the pTV-VSVNJ(rwt) by the T7 RNA polymerase.
The restriction enzyme sites shown in Fig. 7 are included in
each fragment and were used to assemble the full-length clone.
Subclones of A, B, F and G fragments (Fig. 7) were generated in
the pBKS vector by RT-PCR using the genomic RNA isolated
from the purified VSVNJ(Haz). The fragments of C, D and E
(Fig. 7) were generated by PCR using the cDNA clone of each
gene as a template and were cloned into pBKS. The primers
(numbers 1 to 15) used for the RT-PCR and PCR are described
in Fig. 7. All subclones were sequenced and compared with the
sequences of VSVNJ gene clones which were previously used
successfully for the recovery of DI particles (Kim et al., 2002).
Segment A was generated by the megaprimer PCR method
using three separate primers. A small, double-stranded DNA
fragment containing the T7 transcriptional promoter and 3′
genomic terminal sequences was amplified by PCR using the
pTVas a template and primers 1 and 2 (Fig. 7). The small PCR
product was used as a megaprimer, pairing with primer 3 to
amplify the fragment A.
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(M48R+M51R), pTV-VSVNJ(M;M48R) and pTV-VSVNJ(M;
M48R+M51R), were generated by replacing the M(wt) gene
with the M gene containing the respective mutations. The M
gene cDNAs containing the mutations were amplified using
primers 8 and 9 (Fig. 7) and pBKS-MNJ(M48R) and pBKS-MNJ
(M48R+M51R) as templates. The full-length cDNA clone was
digested partially with PacI first and then completely digested
with NotI. The PCR products were cut with the same restriction
enzymes and cloned into the full-length cDNA clone. The
nucleotide changes were confirmed by DNA sequencing.
Generation of inducible cell lines expressing wild type or
mutant VSVNJ M proteins
The human embryonic kidney 293 cells expressing M(wt) or
M proteins with M to R mutations were generated by using the
Flp-In T-Rex Core Kit (Invitrogen) according to the manufac-
turer's manual. Briefly, the Flp-In T-Rex 293 cell line
(Invitrogen) expressing the Tet repressor and containing the
Flp recombinase target sequence in its genome was used as a
parental cell line. The 293 parental cell line was cotransfected
with the pcDNA5-MNJ(wt), pcDNA5-MNJ(M33R), pcDNA5-
MNJ(M48R), pcDNA5-MNJ(M51R) or pcDNA5-MNJ(M48R+
M51R) and pOG44 encoding Flp recombinase. Several cell
colonies which were formed in the presence of the selective
agents blasticidine (15 μg/ml) and hygromycin B (400 μg/ml)
were isolated, expanded and checked for the expression of M
proteins in the presence of tetracycline (1 μg/ml).
Recovery of DI particles and recombinant VSVNJ from cDNA
VSVNJ DI particle NJDI(227-188) was recovered from
cDNA by cotransfecting pBKS-NNJ, pBKS-PNJ, pBKS-MNJ
(wt) or pBKS-MNJ(M-R mutants), pBKS-GNJ, pBKS-LNJ and
pTV-NJDI(227-188) as described previously (Kim and Kang,
2005). Recombinant VSVNJ expressing wild type or mutant M
protein was recovered from the plasmid DNA by the reverse
genetics method employing the BHK cell line expressing
bacteriophage T7 RNA polymerase BSR T7/5 (Harty et al.,
2001). BSR T7/5 cells were seeded in a 100 mm culture dish to
be approximately 90% confluent in 24 h. The cells were
maintained in DMEM supplemented with 5% FBS without
antibiotics. The transfection was carried out with Lipofecta-
mine™ 2000 (Invitrogen) according to the manufacturer's
protocol. Briefly, the BSR T7/5 cells were contransfected with
10 μg of pBKS-IRES/NNJ, 10 μg of pBKS-IRES/PNJ, 5 μg of
pBKS-IRES/LNJ and 15 μg (1.6 pmol) of one of the following
plasmids: pTV-VSVNJ(rwt), pTV-VSVNJ(M;M48R) or pTV-
VSVNJ(M;M48R+M51R). The culture media was harvested
when more than 50% of cells showed cytopathic effects,
approximately 48 h after transfection.
Apoptosis assay
Inducible cell lines expressing M(wt), M(M48R), M(M51R)
and M(M48R+M51R) of VSVNJ were grown in 60-mm dishuntil 95% confluency, at which time they were treated with
1 μg/ml of tetracycline for 24 h to induce the expression of M
proteins. Cell lysates were prepared to isolate low molecular
weight DNA for the DNA fragmentation assay and to measure
the caspase-3 activity in the cell lysate. For the DNA
fragmentation assay, cells were lysed in 300 μl of TE/Triton
buffer [0.2% (v/v) Triton X-100, 10 mM Tris pH 8.0 and 1 mM
EDTA]. The cell lysates were treated with RNase A (1.5 μl of
10 mg/ml solution) for 1 h at 37 °C. Sodium dodecyl sulfate
(12.5 μl of 10% solution) and proteinase K (2 μl of 20 μg/ml
solution) were added to the cell lysates and were incubated for
1 h at 50 °C. The low molecular weight DNAwas extracted by
treating the lysate with the same volume of phenol/chloroform/
isoamylalcohol and concentrated by precipitating the DNAwith
0.1 volume of 3 M sodium acetate and 2.5 volume of 100%
ethanol. The DNA pellet was dissolved in dH2O. The DNAwas
resolved on a 1.5% agarose gel containing ethidium bromide.
Caspase-3 activities from the cell lysates were measured using
the BD ApoAlert™ Caspase Colorimetric Assay kit (BD
Biosciences Clontech) according to the manufacturer's proto-
col. Briefly, the cells were lysed in 100 μl lysis buffer, protein
concentration of the cell lysates was determined by the Bradford
method using the Bio-Rad Protein Assay kit (Bio-Rad) and
500 μg of each sample was measured for the caspase-3 activity.
All assays were done in triplicate.
Determination of protein expression
Expression of matrix proteins in inducible cell lines was
determined by both Western blot analysis and immunoprecipi-
tation analysis. Western blot analysis was carried out using
10 μg of cell lysate and ECL Plus Western Blotting Detection
reagents (Amersham Biosciences). The level of GAPDH in the
35S-met labeled cell lysate was determined by Western blot
analysis using a purified goat polyclonal antibody raised against
a internal peptide of human GAPDH (Santa Cruz Biotechnol-
ogy, Inc.). Determination of total cellular protein synthesis after
viral infection, immunoprecipitation of M proteins, VSVNJ
proteins and human heat shock protein 70 (HSP70) was carried
out after labeling the cells with 30 μCi/ml of 35S-met (1175 Ci/
mmol, PerkinElmer). VSVNJ proteins were immunoprecipitated
with rabbit polyclonal antisera against VSVNJ total proteins and
the L protein (Kim et al., 2002; Kim and Kang, 2005). HSP70
was immunoprecipitated with a mouse monoclonal antibody
against HSP70 (Santa Cruz Biotechnology, Inc.).
Northern blot analysis
Northern blot analysis of DI particle genomic RNAs in the
infected cells was performed as described previously (Kim et
al., 2002).
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